Anthem Blue Cross and Blue Shield

Part B Updates for Praluent, Repatha, and Sylvant

Anthem Blue Cross and Blue Shield is adding the following three new injectable drugs to the 2016 Medicare Advantage list of Part B Injectables / Infusibles requiring prior authorization. As of 01/01/2016, providers must call for prior authorization of these drugs.

Drugs billed with NOC HCPCS J code (J3490 and J3590)

1. Praluent (alirocumab): used to reduce serum low-density lipoprotein cholesterol (LDL-C) - (unlisted, no J code established at this time)
2. Repatha (evolocumab): used to reduce serum low-density lipoprotein cholesterol (LDL-C) - (unlisted, no J code established at this time)
3. Sylvant (siltuxumab): for treatment of Multicentric Castleman’s disease (MCD) (C9455)

Please note two of these drugs are currently billed under the Not Otherwise Classified J code (J3490 and J3590). Since this code includes all drugs NOC, the plan’s denial will be for the drug, and not the HCPCS.

This update to the 2016 prior authorization requirement applies to all of Anthem’s Medicare Advantage plans.